Who are Latanoprost, Dorzolamide's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/latanoprost-dorzolamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Latanoprost, Dorzolamide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Latanoprost, Dorzolamide (Latanoprost, Dorzolamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog + Carbonic anhydrase inhibitor combination. Area: Ophthalmology.

marketed Prostaglandin analog + Carbonic anhydrase inhibitor combination Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Latanoprost, Dorzolamide (Latanoprost, Dorzolamide) — Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. This combination reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor (latanoprost) and decreasing aqueous humor production (dorzolamide).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Latanoprost, Dorzolamide TARGET	Latanoprost, Dorzolamide	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	marketed	Prostaglandin analog + Carbonic anhydrase inhibitor combination	Prostaglandin F receptor (FP receptor) and Carbonic anhydrase II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog + Carbonic anhydrase inhibitor combination class)

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Latanoprost, Dorzolamide — Competitive Intelligence Brief. https://druglandscape.com/ci/latanoprost-dorzolamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab